Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Sutro Biopharma
company
About
Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.
- 101 - 250
Details
- Last Funding Type
- Series E
- Last Funding Money Raised
- $85.40M
- Industries
- Biotechnology,Information Technology,Medical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$85.40M
Sutro Biopharma has raised a total of
$85.40M
in funding over 2 rounds. Their latest funding was raised on
Jul 26, 2018 from a Series E round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 26, 2018 | Series E | $85.40M | 1 | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
